Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

XELOX for 4 Months Versus 6 Months as Adjuvant Chemotherapy in Gastric Cancer After D2 Resection (LOMAC)

NCT03399110 is registered in ClinicalTrials.gov with Fudan University as lead sponsor.

NCT NCT03399110
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03399110 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
XELOX for 4 Months Versus 6 Months as Adjuvant Chemotherapy in Gastric Cancer After D2 Resection (LOMAC)
Lead sponsor
Fudan University
Phase
Phase 3
Overall status
Completed
Start date
January 14, 2018
Completion date
August 15, 2026
Enrollment
1,024 (actual)
Sites
10

Conditions

As the registry lists them; a condition with its own page is linked.

gastric cancer